Achieve exceptional IVT results with Codex® HiCap RNA Polymerase, a co-transcriptional capping RNA polymerase that has been uniquely engineered to produce synthetic mRNA at high yield and low immunogenicity.
More translatable mRNA with greater capping efficiency
Specifically designed to improve capping efficiency over current methods while reducing cap analog requirements, the Codex® HiCap RNA Polymerase increases yields of fully capped mRNA without compromising the total RNA yield.
Reduced immunogenicity from double-stranded RNA
Reduce the negative immune responses from your vaccine and therapeutic candidates with Codex® HiCap RNA Polymerase, which produces significantly less double-stranded RNA (dsRNA) compared to wild-type T7 RNA polymerase.
Flexible uracil analog incorporation
Codex® HiCap RNA Polymerase incorporates commonly used uracil analogs to replace canonical uracil (which can also elicit unintended immune response) during IVT and is able to incorporate a range of commercial uracil analogs.
OEM enzyme supply
You can tailor Codex® HiCap RNA Polymerase purchase quantities, concentrations and fill-volumes to meet your demands and integrate seamlessly into your IVT production process. To learn more, please contact us, or visit the Scale-up and Supply page.
Looking for another engineered life science enzyme?
Sequencing & detection
Codexis’s novel enzymes are engineered to improve accuracy, speed, and overall robustness of your sequencing or diagnostic workflows such as NGS library preparation or RT-qPCR.
DNA & RNA synthesis
Our next-generation enzymes improve yield, speed and cost of oligonucleotide synthesis. We have worked on single and double-stranded ligases, polymerases, nucleases, and others.
We enable novel biosensors for human and environmental monitoring. Through the directed evolution of biomolecules, we can unlock the full potential of your device and revolutionize quality of life.